about
Ubc13: the Lys63 ubiquitin chain building machineInterplay between Ubiquitin, SUMO, and Poly(ADP-Ribose) in the Cellular Response to Genotoxic StressUnderstanding specific functions of PARP-2: new lessons for cancer therapyHomeodomain-Interacting Protein Kinase-2: A Critical Regulator of the DNA Damage Response and the EpigenomeRole of MDM2 and MDMX in DNA repairA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursImaging the DNA damage response with PET and SPECTSynergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathwayDNA Repair Pathway Alterations in Bladder Cancer.Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.Revisiting the hallmarks of cancer.Taking a Bad Turn: Compromised DNA Damage Response in LeukemiaDDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses.PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.Anti-cancer effects of vitamin C revisited.miR-638 suppresses DNA damage repair by targeting SMC1A expression in terminally differentiated cellsExcerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Aberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival.The Mre11-Nbs1 Interface Is Essential for Viability and Tumor Suppression.A signature motif in LIM proteins mediates binding to checkpoint proteins and increases tumour radiosensitivity.ATM protein is deficient in over 40% of lung adenocarcinomas.PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas.PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.Proteomics insights into DNA damage response and translating this knowledge to clinical strategies.Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.DNA damage response is hijacked by human papillomaviruses to complete their life cycleThe 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.Looking beyond the cancer cell for effective drug combinations.Relative Contributions of Herpes Simplex Virus 1 ICP0 and vhs to Loss of Cellular IFI16 Vary in Different Human Cell Types.53BP1 fosters fidelity of homology-directed DNA repair.Insight into the ERVK Integrase - Propensity for DNA Damage.Checkpoint-dependent phosphorylation of Med1/TRAP220 in response to DNA damage.POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologiesModulation of the DNA damage response during the life cycle of human papillomaviruses.
P2860
Q26739716-6D0C2C1A-3293-4F28-AB97-8E765902FE5CQ26752447-9EBB1E4B-8076-4514-8647-7DB37C535397Q28067486-1D3F345E-9C5C-432E-9256-2110029FD17AQ28073422-9CCD5DF5-E414-40AA-B0D1-99F799F33FE7Q28079939-FB083F94-61E0-475A-B77C-E9602386A0ACQ33439527-1F351C76-5AC8-4A5B-ADB0-87F915637A51Q33581909-8B94C2B5-BB8F-4781-82E3-DCE6D1D705F1Q33597926-5DC38811-4A19-443F-852F-D851BE67316BQ33607945-6228A189-902B-42D4-AC9A-9051B0EA0496Q33618432-C03320A0-5862-40CE-96C1-82ACC3172295Q33624824-0DA0E833-3F08-46A3-BD51-2C54ABDFB77CQ33685138-A955BA29-3EAB-480B-9F17-53694E2D88F3Q33732986-2D5447F3-A835-4D9C-8B05-A8C111C98A06Q33855938-D269F1F3-1CAF-40CB-90B6-2D20799C7130Q34538231-C448AC07-AACC-4C4C-BA75-AEDDE0495548Q36080277-EA1494FA-5B3A-4CA0-B5F9-0894FCFC0FABQ36583169-1C09D813-A4FE-478B-8573-4F6B5B806743Q36665804-C3737846-1BD5-4FFA-BF41-43CB7FE0283EQ37194235-82160DCB-29BB-44E0-B987-C534813E0197Q37349280-BE873FCA-59BD-4D81-AAAD-0C29BF068A67Q37552296-F22B5E2F-1E9B-43B5-8F68-16E889C57ADEQ37585721-A4E534B7-FE46-4FFE-9FAD-040FC9BF8940Q37595154-B1AA9B26-81AA-48CF-A711-76D5B3B6D1DAQ37628924-D5550FD2-1465-4BCA-9E0E-CE2F6E9AFB87Q37633440-A8C95C4C-EBE9-46E9-A09F-D39C7CE6995FQ37665592-D9287C73-3910-4829-9CB0-C3C67ECD6A0AQ37676851-DB1B1DCE-A319-495E-AF8F-D843C9FF86D0Q37678950-1D4F1C1D-F356-4F0E-A292-6F6CD18EC9F6Q37684589-527249F9-52A1-4034-94B1-5436CC22C228Q37724792-ECD3B8CA-C65D-4ED8-A15A-474B67C1C806Q38652190-4447BA9E-3AE4-4B80-A0F8-41AACD8D9744Q38702556-26F8AB45-8EB3-42F5-B887-8BE0E0512AF3Q38718686-867A24D8-3138-43D1-9AE7-BA257384FBC2Q38728970-4F403682-4436-4CB4-BF47-AB7F071706BDQ38758315-3D782310-AC6A-4A9C-B020-33FF26EBFC42Q38761656-58EE9896-AD43-4340-BCA3-996874DE7A39Q38781083-2C29000A-2954-44B0-899D-90A3AE313194Q38826664-76B98483-7919-4C9C-8BFA-6770D443C44AQ38870074-61B6DFE4-3159-41AE-AF8C-97C32EB467BCQ39005827-B38B365F-129F-4A2C-9EC8-0EE089253EF6
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting the DNA Damage Response in Cancer
@ast
Targeting the DNA Damage Response in Cancer
@en
Targeting the DNA Damage Response in Cancer
@nl
type
label
Targeting the DNA Damage Response in Cancer
@ast
Targeting the DNA Damage Response in Cancer
@en
Targeting the DNA Damage Response in Cancer
@nl
prefLabel
Targeting the DNA Damage Response in Cancer
@ast
Targeting the DNA Damage Response in Cancer
@en
Targeting the DNA Damage Response in Cancer
@nl
P3181
P1433
P1476
Targeting the DNA Damage Response in Cancer
@en
P2093
Mark J. O’Connor
P304
P3181
P356
10.1016/J.MOLCEL.2015.10.040
P407
P577
2015-11-19T00:00:00Z